20.1 Breast Disease, Triple Assessment, and Breast Cancer

Key Takeaways

  • Refer a discrete breast lump or other concerning finding through the NCCP symptomatic pathway. Document the findings so the clinic can triage and arrange appropriate tests.

  • BreastCheck is free population screening for eligible asymptomatic people aged 50 to 69, with invitations about every two years. A new suspicious symptom requires assessment even after a normal screen.

  • Triple assessment combines examination, diagnostic imaging and tissue sampling when indicated. A persistent suspicious finding requires reassessment even with normal imaging or a discordant benign result.

  • Suspected bacterial lactational mastitis needs supportive care and appropriate antibiotics with reassessment. A collection may need drainage. Persistent refractory nipple eczema or suspicious diffuse skin changes warrant breast assessment.

  • Use receptor status and recurrence risk to choose systemic treatment. Consider bone protection with aromatase inhibitors and monitor cardiac function with trastuzumab.

Last updated: November 2026

Assess a breast symptom and choose the Irish pathway

Start by characterising the symptom. Ask when a lump appeared, whether it changes with the menstrual cycle, whether nipple discharge is spontaneous, unilateral or bloody, and whether there has been recent pregnancy, breastfeeding, injury or surgery. Ask about previous imaging, breast cancer and relevant family history. A recent normal screen does not resolve a new finding.

The three components of triple assessment

  1. Clinical assessment. Explain the examination, obtain and record consent, ask if the patient wants a chaperone and record their wishes. Inspect the breasts and nipples for asymmetry, retraction, dimpling, crusting or oedema. Raised arms or contraction of the pectoral muscles can make tethering clearer. Palpate all quadrants, the axillary tail, the subareolar region and the axillary and supraclavicular nodes. Document clock-face position, distance from the nipple, size, mobility and associated changes. A smooth mobile lesion can still need investigation. Medical Council professional guidance
  2. Diagnostic imaging. The breast team chooses imaging based on age, pregnancy or lactation, and the clinical finding. Ultrasound is usually first in younger patients and for a palpable lesion during pregnancy or lactation. Mammography is useful in older patients, often with targeted ultrasound for a focal finding. Two-view mammography uses craniocaudal and mediolateral oblique views. Dense tissue can obscure a lesion on a mammogram. A suspicious examination or ultrasound finding may warrant mammography at a younger age or during pregnancy or lactation after specialist assessment. An Irish service example is St Vincent's Private Hospital, which describes mammography from age 35 in its triple assessment clinic. The national GP referral criteria do not use that imaging threshold to decide whether to refer a discrete lump. Irish clinic pathway · European Society of Breast Imaging practice recommendations
  3. Tissue sampling when indicated. Core needle biopsy retains architecture, which helps distinguish invasive carcinoma from in-situ disease and permits grading and biomarker testing. Ultrasound guidance is used for a sonographically visible target. Stereotactic or other image guidance and vacuum-assisted sampling can be used for mammographic abnormalities such as calcifications. Axillary node assessment may use needle aspiration or core biopsy. Aspiration of a symptomatic cyst can relieve pain, with further assessment if it is bloody, fails to collapse or recurs. Cytology alone cannot reliably distinguish an in-situ primary from an invasive one. For invasive cancer, ER and PR are assessed by immunohistochemistry. HER2 is assessed by immunohistochemistry with in-situ hybridisation used to resolve equivocal results. NCCP diagnosis and staging · ASCO/CAP HER2 guidance

Caution

A persistent suspicious examination requires further assessment even with normal mammography and ultrasound. The NCCP advises clinically guided core biopsy in this setting. Discordance between a suspicious examination or imaging and benign pathology requires specialist review of whether the sample explains the lesion, with repeat or excision biopsy when indicated. MRI can be considered after multidisciplinary review for persistent suspicious unilateral discharge or Paget disease with unrevealing conventional imaging, or for preoperative staging when disease extent is unclear. It has a selective role after initial assessment.

NCCP symptomatic referral and BreastCheck

GP findingDecision under the Irish NCCP pathway
Discrete lump identified on examinationRefer electronically to a Symptomatic Breast Disease Clinic. The clinic triages the referral from the clinical details
Patient notices a lump, GP examination is normalConsider reassessment at another time in the cycle. Refer when concern persists. Follow the relevant pathway for any additional sign
Suspicious axillary lump, focal asymmetric nodularity that persists beyond one menstrual cycle, or suspected breast abscessRefer to the symptomatic clinic and arrange urgent clinical care as indicated by the presentation
Unilateral bloody or spontaneous serous discharge, new fixed nipple retraction, persistent nipple eczema despite topical treatment, skin dimpling or peau d'orangeRefer to the symptomatic clinic
Breast pain alone and normal examinationOffer advice and safety-netting. At age 35 or above, consider a mammography-only referral if pain persists after three months

Use Healthlink or the supported GP software. Describe the exact findings and their duration. BreastCheck offers free population screening to eligible asymptomatic people aged 50 to 69, including women and some transgender, non-binary and intersex people with breast tissue under the HSE criteria. Its usual invitation interval is about two years. A 58-year-old with a new hard lump needs the symptomatic pathway even with a screening appointment next month and a normal screen six months ago. A younger adult with a discrete lump also qualifies for symptomatic referral. NCCP GP referral guideline · HSE BreastCheck eligibility

Distinguish benign, inflammatory and malignant breast presentations

ConditionClinical or imaging clueManagement after appropriate assessment
FibroadenomaSmooth, firm, mobile lump, common in younger adults. A typical ultrasound appearance is a circumscribed oval mass, wider than tallConcordant benign lesions are usually managed conservatively. Review substantial growth, symptoms, discordant findings or suspected phyllodes tumour with the breast team
Simple cystCircumscribed anechoic lesion with posterior acoustic enhancement. May fluctuate in size or cause focal painAn asymptomatic simple cyst generally needs no intervention. Consider aspiration for symptoms. Bloody fluid, a residual mass or rapid recurrence requires reassessment
Fat necrosisMay follow injury, breast surgery or radiotherapy. An oil cyst can be diagnostic on imaging, but an irregular mass, tethering or spiculated calcification can mimic cancerUse core biopsy when appearances are suspicious or discordant. Reassure when the clinical, imaging and any pathology findings agree
Intraductal papillomaA papillary lesion can cause spontaneous, unilateral single-duct serous or bloody dischargeRefer as a suspicious symptom. Specialist imaging and sampling establish the diagnosis. Atypia, persistent symptoms and discordance help determine whether the team recommends vacuum-assisted removal, surgical excision or surveillance
Duct ectasiaDilated subareolar ducts can produce thick green or brown discharge and longstanding retractionReassure after appropriate assessment. New fixed retraction or unilateral bloody discharge still requires referral. Discuss persistent troublesome discharge with the breast team
Periductal mastitisPeriareolar inflammation, recurrent subareolar abscess or a draining fistula, associated with smokingArrange specialist assessment of a collection or persistent lesion. Drain a collection as indicated and use antibiotics according to clinical severity, cultures and local policy. Offer smoking cessation support. A recurrent fistula may require surgery

Phyllodes tumours are fibroepithelial tumours that may resemble a fibroadenoma and may enlarge rapidly. Core biopsy can report an indeterminate fibroepithelial lesion. Refer for specialist excision when phyllodes is suspected. Aim for complete removal, with the margin plan guided by whether the tumour is benign, borderline or malignant. Borderline and malignant tumours can recur and malignant tumours can spread haematogenously. Fibroepithelial lesions guideline · Association of Breast Surgery phyllodes guidance · European B3 lesions guideline · American Society of Breast Surgeons simple-cyst guidance · Periductal mastitis guidance

Lactational mastitis and breast abscess

Lactational breast inflammation can cause focal pain, warmth, induration and systemic symptoms. Review feeding, oversupply, nipple trauma and the evolution of symptoms. Support responsive breastfeeding, use cold packs and offer paracetamol or ibuprofen if suitable. If needed, express enough for comfort or the baby's needs. Excessive pumping, deep massage and attempts to empty the breast can worsen inflammation.

Consider antibiotics when bacterial mastitis is suspected, for example with persisting focal signs and systemic illness. For non-severe community treatment, HSE AMRIC lists flucloxacillin 500 mg to 1 g orally every six hours for five days then reassess, or clindamycin 300–450 mg orally every six hours for the same initial period in penicillin allergy. Review at or within 48 hours if there is no improvement. If improving but incompletely resolved at day five, consider extending treatment to a maximum of ten days under this pathway. Assess severe illness for urgent hospital treatment.

Suspect an abscess with a discrete tender mass or persistent focal signs despite appropriate treatment. Arrange breast assessment and ultrasound. Drain a confirmed collection, usually with image-guided aspiration where feasible, and send pus for culture. Some collections need repeat aspiration, catheter drainage or surgery, depending on response, size and skin condition. Support ongoing breastfeeding or expression and give antibiotics according to severity and the clinical setting. Persistent or atypical inflammation warrants reassessment for other diagnoses. HSE AMRIC lactational mastitis · HSE lactation and abscess guidance

Recognise malignant skin and nipple changes

  1. Paget disease of the nipple. A persistent unilateral scaly, crusted, erythematous or ulcerated nipple lesion can spread to the areola. It may itch, burn or bleed. The NCCP advises symptomatic referral for nipple eczema refractory to topical treatment. Absence of a lump does not lower the need for assessment. Breast imaging evaluates underlying disease and a punch or wedge biopsy of the affected nipple or areola can identify malignant intraepidermal Paget cells. Most cases are associated with underlying DCIS or invasive carcinoma. The NCCP notes that in a minority no other underlying tumour is found. Consider MRI after multidisciplinary discussion when conventional imaging is normal. NCI Paget disease diagnostic guidance
  2. Inflammatory breast cancer. Rapid breast enlargement, diffuse erythema and oedema or peau d'orange, often without a discrete lump, require prompt assessment. The classic staging presentation involves at least one-third of the breast and histological evidence of invasive cancer. Dermal lymphatic tumour emboli explain the oedema but can be patchy. The specialist team uses imaging, core biopsy and, where appropriate, skin punch biopsy. Lack of dermal emboli on a punch sample does not exclude the diagnosis. Marked suspicious findings at presentation or persistent unexplained inflammation after treatment require prompt breast referral. NCCP diagnosis and staging · Inflammatory breast cancer expert diagnostic criteria
Loading diagram...
Symptomatic Breast Referral and Triple Assessment Pathway

Breast cancer pathology, staging and treatment

From tissue diagnosis to staging

  • Invasive breast carcinoma of no special type (NST) is the commonest invasive type. A spiculated lesion is suspicious, but imaging alone does not establish histological type.
  • Invasive lobular carcinoma often shows loss of E-cadherin and single-file infiltration. It can be difficult to define mammographically and can be multifocal. If conventional imaging and examination disagree on extent or density obscures sizing, the multidisciplinary team can consider preoperative MRI. Irish guidance advises selective use of preoperative MRI after biopsy.
  • Ductal carcinoma in situ (DCIS) is a malignant epithelial proliferation confined to the ducts without stromal invasion. Suspicious calcifications may be the first clue. Extent, margin status and risk inform breast-conserving surgery with consideration of radiotherapy, or mastectomy for extensive disease.

The pathology team assesses histological grade and receptor status. Stage describes local tumour extent, regional nodes and distant spread. Axillary ultrasound can identify abnormal nodes for needle sampling. Stage and symptoms guide distant staging. An asymptomatic patient with low-stage disease generally does not need routine distant imaging. NCCP diagnosis and staging · NCI breast cancer pathology and staging

Local treatment and axillary morbidity

TreatmentDecision and consequences
Breast-conserving surgeryExcise the tumour with clear margins when technically feasible and acceptable to the patient. Adjuvant radiotherapy reduces local recurrence. NCCP allows discussion of omission in selected very low-risk patients, such as a patient over 65 with grade 1–2, T1, node-negative luminal A disease. The team can select a partial-breast technique for eligible patients
MastectomyConsider for extensive disease, inability to obtain clear margins with acceptable breast conservation, or patient preference. Discuss reconstruction when appropriate. NCCP recommends postmastectomy radiotherapy in high-risk node-positive disease and advises consideration in intermediate-risk patients with one to three involved nodes
Sentinel node biopsy and axillary treatmentSentinel node biopsy can stage a clinically node-negative axilla when the result would inform care. Select low-risk cases may omit surgical staging after specialist discussion. The NCCP advises considering axillary radiotherapy in place of dissection after upfront surgery for cT1–2 disease with one or two sentinel nodes containing macrometastases. The team takes account of burden, initial stage, surgery and neoadjuvant therapy

Axillary dissection can cause lymphoedema, shoulder dysfunction or sensory loss from intercostobrachial nerve injury. Long thoracic nerve injury can weaken serratus anterior and cause scapular winging. Thoracodorsal nerve injury can weaken latissimus dorsi. Assess new swelling, heaviness or tightness and refer for lymphoedema care. A single ipsilateral BP reading is not an absolute contraindication after axillary treatment. For venepuncture or IV access, consider the other arm when practical, the presence of lymphoedema, clinical need and available alternatives. NCCP radiation oncology guideline v4 · ASCO axillary staging guideline · American College of Surgeons axillary anatomy · All-Ireland Lymphoedema Guidelines

Receptor-directed systemic treatment and genetics

  1. ER-positive invasive disease. Tamoxifen, commonly 20 mg daily, is an option before menopause. Recurrence risk and patient preferences can support ovarian suppression with tamoxifen or with an aromatase inhibitor. Aromatase inhibitor monotherapy requires a postmenopausal setting. Anastrozole or letrozole is commonly used after menopause, particularly at medium or high recurrence risk. Tamoxifen is an option at low recurrence risk or when aromatase inhibitors are unsuitable. Adjuvant endocrine treatment commonly starts with a five-year plan and the team can consider extension. With tamoxifen, discuss hot flushes, thromboembolism and endometrial pathology, and investigate abnormal bleeding. Avoid strong CYP2D6 inhibitors such as paroxetine and fluoxetine when possible because they reduce endoxifen exposure. With aromatase inhibitors, counsel about arthralgia and bone loss. Assess fracture risk and baseline bone density as appropriate, ensure adequate calcium and vitamin D, and consider bone-protective treatment according to risk and the cancer plan. NCCP breast systemic regimens · NCCP tamoxifen regimen · Tamoxifen interaction study · NICE NG101 endocrine and bone guidance
  2. HER2-positive disease. Trastuzumab is an HER2-targeting antibody, often used with chemotherapy in early disease. Pertuzumab is added for eligible higher-risk cases. The EU product information specifies one year of trastuzumab for early disease or until recurrence, whichever occurs first. Check cardiac function at baseline and about every three months during treatment. For Herceptin, if LVEF falls by at least 10 percentage points from baseline and to below 50%, suspend treatment and repeat the assessment in about three weeks. Refer for cardiology assessment and follow the post-treatment cardiac monitoring plan. Anthracyclines add cardiotoxicity. Follow the approved regimen and sequencing for the indication. EMA Herceptin product information
  3. Triple-negative disease and inherited risk. ER-negative, PR-negative and HER2-negative cancers lack the standard endocrine and trastuzumab targets. For eligible high-risk early or locally advanced triple-negative disease, NCCP regimens pair neoadjuvant chemotherapy with pembrolizumab and continue pembrolizumab after surgery. Adjuvant olaparib is an option for eligible high-risk, HER2-negative early disease with a pathogenic germline BRCA1/2 variant after chemotherapy. Young onset, multiple primary tumours, male breast cancer or a strong family history may prompt cancer genetics referral. Oncology-directed testing for a PARP inhibitor and hereditary-risk assessment have separate eligibility criteria. A pathogenic variant can lead to family counselling, enhanced surveillance and discussion of risk-reducing breast and ovarian surgery. NCCP PARP inhibitor testing guidance · NCI inherited risk management

Mastalgia, male breast symptoms and survivorship

For isolated mastalgia with a normal examination, offer a well-fitting bra, simple analgesia or a topical NSAID if suitable, and safety-netting. Focal pain reproduced on palpation of the chest wall can suggest a musculoskeletal source. A new lump or skin or nipple change changes the assessment. True gynaecomastia is palpable glandular tissue centred under the nipple. Review medicines such as spironolactone or antiandrogens, anabolic steroids, and possible endocrine, liver or testicular causes. A hard eccentric mass, nipple retraction or bloody discharge warrants assessment for male breast cancer. BRCA2 is an inherited risk factor. NCCP GP referral guideline · HSE breast pain guidance · European Academy of Andrology guidance

The NCCP recommends a surgical clinical follow-up at one year and a treatment summary and care plan. The GP should refer urgently to the appropriate breast or oncology service for suspected recurrence. In the routine imaging pathway, an eligible patient diagnosed at 61 with ER-positive, HER2-negative invasive disease may transition to BreastCheck after three annual symptomatic-service mammograms. Those still under 50 continue annual symptomatic surveillance until eligible. Those older than 69 after three years generally continue for two additional years. The usual symptomatic-service duration for DCIS, triple-negative and HER2-positive disease is five years. High familial risk, bilateral mastectomy and other individual circumstances can change the plan. Discuss troublesome vasomotor or genitourinary symptoms with the cancer team and start with appropriate non-hormonal options. NCCP post-treatment follow-up

Test Your Knowledge

A 56-year-old woman attends her general practitioner after noticing a firm, painless, 2.5 cm lump in the upper outer quadrant of her left breast 3 weeks ago. Her routine BreastCheck screening invitation is scheduled for 5 months from now, and her last screening mammogram 19 months ago was reported as normal. On examination, there is a discrete, hard, non-mobile mass with subtle overlying skin dimpling. What is the single most appropriate next management step?

A

Reassure the patient that a normal mammogram 19 months ago excludes significant pathology and advise waiting for her upcoming BreastCheck appointment

B

Send the NCCP electronic referral to a Symptomatic Breast Disease Clinic, documenting the hard fixed lump and skin dimpling.

C

Perform a fine-needle aspiration in the general practice surgery and arrange routine follow-up if cytology is atypical

D

Order an outpatient bilateral mammogram alone and discharge her from follow-up if the mammogram is reported as normal

Test Your Knowledge

A 29-year-old, four weeks postpartum and breastfeeding, reports three days of worsening focal breast pain and redness with rigors. Temperature is 38.4°C, pulse 90/min and BP 116/74 mmHg. She is alert, drinks normally, has no penicillin allergy and has no palpable fluctuant mass. The GP assesses her as suitable for community treatment of suspected bacterial lactational mastitis. Which plan is most appropriate?

A

Advise immediate cessation of breastfeeding from both breasts, prescribe oral co-amoxiclav, and arrange urgent surgical incision and drainage

B

Prescribe a 5-day course of topical fusidic acid cream to the nipple and withhold systemic antibiotics to protect the infant

C

Perform an immediate mammogram and discontinue breastfeeding until malignancy is excluded by core biopsy

D

Start oral flucloxacillin every six hours for five days then reassess, offer analgesia and support responsive breastfeeding, and review sooner if symptoms worsen or fail to improve.

Test Your Knowledge

A 64-year-old woman presents with a 4-month history of a persistent, scaly, crusted, erythematous rash restricted to her right nipple and inner areola. Her general practitioner prescribed 1% hydrocortisone cream 6 weeks ago, which produced no improvement. She has no palpable breast mass, and her left nipple is completely normal. What is the most appropriate next step?

A

Refer to a Symptomatic Breast Disease Clinic for assessment of possible Paget disease, including breast imaging and nipple biopsy as indicated.

B

Escalate to superpotent clobetasol propionate 0.05% ointment twice daily for 4 weeks to treat refractory nipple eczema

C

Swab the crust for Candida albicans and prescribe oral fluconazole for 14 days without imaging

D

Reassure the patient that unilateral nipple dermatitis in the absence of a palpable mass is benign and arrange review in 6 months

Test Your Knowledge

A 61-year-old postmenopausal woman undergoes breast-conserving excision and sentinel node biopsy for a 1.8 cm, ER-positive, PR-positive, HER2-negative, node-negative invasive carcinoma. Oncology estimates an intermediate risk of recurrence and recommends standard adjuvant endocrine therapy. She has no contraindication to an aromatase inhibitor, has not had a baseline bone-density assessment and is not receiving adjuvant bisphosphonates. Which drug and assessment are most appropriate?

A

Tamoxifen for 5 years, with 3-monthly echocardiographic monitoring of left ventricular ejection fraction

B

Trastuzumab for 12 months, with annual endometrial thickness ultrasound surveillance

C

Letrozole or anastrozole, with baseline DXA and fracture-risk assessment to guide bone protection.

D

Single-agent olaparib for 1 year, with no bone or cardiac surveillance required

Sections you finish are checked off in the contents.